U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Uppsala, Sweden, Nov. 02, 2016 -- Oasmia Pharmaceutical AB (NASDAQ:OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extended its loan to the company and also significantly improved the interest terms.
The current loan from Nexttobe amounts to MSEK 94.4 and is due on December 31, 2016. The new loan replaces the current at due date and amounts, including the accrued interest for 2016, to MSEK 102.4 in total, and is due for payment on September 30, 2017. The interest for the new loan is set at 3.5 %.
Notes to editors:
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
Julian Aleksov Tel: +46 18 50 54 40 E-mail: [email protected]
